SLC5A1 and cardiac hypertrophy: Cardiomyocyte-specific overexpression of SGLT1 in non-diabetic mice resulted in development of cardiac hypertrophy and failure, characterized by accumulation of fibrosis, increased LVEDD and reduced FS proportionately with the increase in the expression of SGLT1 [20].